Show simple item record

dc.contributor.authorBharti, AR
dc.contributor.authorWoods, SP
dc.contributor.authorEllis, RJ
dc.contributor.authorCherner, M
dc.contributor.authorRosario, D
dc.contributor.authorPotter, M
dc.contributor.authorHeaton, RK
dc.contributor.authorEverall, IP
dc.contributor.authorMasliah, E
dc.contributor.authorGrant, I
dc.contributor.authorLetendre, SL
dc.date.accessioned2021-02-12T00:29:25Z
dc.date.available2021-02-12T00:29:25Z
dc.date.issued2016-01-01
dc.identifierpii: hiv-8-093
dc.identifier.citationBharti, A. R., Woods, S. P., Ellis, R. J., Cherner, M., Rosario, D., Potter, M., Heaton, R. K., Everall, I. P., Masliah, E., Grant, I. & Letendre, S. L. (2016). Fibroblast growth factors 1 and 2 in cerebrospinal fluid are associated with HIV disease, methamphetamine use, and neurocognitive functioning. HIV AIDS-RESEARCH AND PALLIATIVE CARE, 8, pp.93-99. https://doi.org/10.2147/HIV.S93306.
dc.identifier.issn1179-1373
dc.identifier.urihttp://hdl.handle.net/11343/260627
dc.description.abstractBACKGROUND: Human immunodeficiency virus (HIV) and methamphetamine use commonly affect neurocognitive (NC) functioning. We evaluated the relationships between NC functioning and two fibroblast growth factors (FGFs) in volunteers who differed in HIV serostatus and methamphetamine dependence (MAD). METHODS: A total of 100 volunteers were categorized into four groups based on HIV serostatus and MAD in the prior year. FGF-1 and FGF-2 were measured in cerebrospinal fluid by enzyme-linked immunosorbent assays along with two reference biomarkers (monocyte chemotactic protein [MCP]-1 and neopterin). Comprehensive NC testing was summarized by global and domain impairment ratings. RESULTS: Sixty-three volunteers were HIV+ and 59 had a history of MAD. FGF-1, FGF-2, and both reference biomarkers differed by HIV and MAD status. For example, FGF-1 levels were lower in subjects who had either HIV or MAD than in HIV- and MAD- controls (P=0.003). Multivariable regression identified that global NC impairment was associated with an interaction between FGF-1 and FGF-2 (model R(2)=0.09, P=0.01): higher FGF-2 levels were only associated with neurocognitive impairment among subjects who had lower FGF-1 levels. Including other covariates in the model (including antidepressant use) strengthened the model (model R(2)=0.18, P=0.004) but did not weaken the association with FGF-1 and FGF-2. Lower FGF-1 levels were associated with impairment in five of seven cognitive domains, more than FGF-2, MCP-1, or neopterin. CONCLUSION: These findings provide in vivo support that HIV and MAD alter expression of FGFs, which may contribute to the NC abnormalities associated with these conditions. These cross-sectional findings cannot establish causality and the therapeutic benefits of recombinant FGF-1 need to be investigated.
dc.languageEnglish
dc.publisherDOVE MEDICAL PRESS LTD
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0
dc.titleFibroblast growth factors 1 and 2 in cerebrospinal fluid are associated with HIV disease, methamphetamine use, and neurocognitive functioning
dc.typeJournal Article
dc.identifier.doi10.2147/HIV.S93306
melbourne.affiliation.departmentPsychiatry
melbourne.affiliation.facultyMedicine, Dentistry & Health Sciences
melbourne.source.titleHIV/AIDS: Research and Palliative Care
melbourne.source.volume8
melbourne.source.pages93-99
dc.rights.licenseCC BY-NC
melbourne.elementsid1079892
melbourne.contributor.authorEverall, Ian
dc.identifier.eissn1179-1373
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record